GH secretion research
1Small studies examined hormone and functional responses in older men.
What does it do?
A GHRH analogue historically approved as Geref for pediatric GH deficiency; contemporary anti-aging use has a different evidence base.
Approved & studied uses
Historical diagnostic use
4Geref evaluated pituitary GH reserve under specialist supervision.
Community uses Reported, unvalidated
Hormonal
18GH release, feedback-preserving stimulation and IGF-1 research.
Body composition
18Lean mass, recovery, skin and age-related GH-decline claims.
Nasal
18Delivery/preference research; variable absorption.
Reasons people report using it; these do not establish benefit.18
Evidence limits
View research →Long-term effects on healthy adults and reliable clinical benefits for sleep, recovery or longevity remain uncertain.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Short-lived local effects
Historical diagnostic label reports facial warmth/flushing and injection-site pain.4
Historical Geref approval; discontinued. FDA determined its withdrawal was not for safety or effectiveness reasons.
Molecular information
Amino-acid sequence
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
Residue count only · sequence not verified3
An exact sequence has not been verified for this formulation.
Length29 amino acids
Molecular weight · Da3357.9 Da
Formula, sequence notation & identity
Molecular formulaC149H246N44O42S3
Amidated GHRH(1–29).
Formula excludes acetate counterions.
Pharmacokinetics
How long does it stay in the body?
Human data
Reported half-life6–7 minutes (intravenous)4
Route / formulationIntravenous Geref diagnostic injection
50%of reference level
Illustrative model using reported human data.
About 3% remaining after 30 min–35 min
Five half-lives in this simplified model. This is not a prediction of when effects stop.
Evidence and model details
The historical Irish label gives a 6–7-minute range. Illustration uses its 6-minute lower bound. This is not a subcutaneous estimate.
Population: Historical diagnostic-product population; age breakdown not specified
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life12 min17
Route / formulationSource page: Injectable. Exact PK route not verified.
The checked IV Geref label gives 6–7 minutes; the reference value is retained separately and must not replace route-specific label data.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 1 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: FDA Geref Label (discontinued)
Source’s reported peak time: 10 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Hormones and function differed
Nighttime GH rose, but IGF-I and body composition did not significantly change; only selected strength/endurance measures improved.1
Reported timelines
Reference & communitySource expectations
IGF-1/sleep 1–2 weeks; composition 2–8; ongoing changes 8–12 weeks to 3–6 months. Anti-aging benefit timeline unvalidated.18
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 9 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “664 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 2 mg | Nightly | GH secretion and muscle outcomesHuman study | 6 weeks | 1 |
Population 11 healthy men, age 64–76, with low baseline IGF-I Context Small before/after study, not a validated anti-aging regimen. | |||||
| SubQ | 200-300 mcg daily | Once at bedtime | Anti-aging/LongevityReference report | 3-6 months continuous use, then 1-3 month break to prevent desensitization | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance. Source tabs Injectable | |||||
| SubQ | 300-500 mcg daily | Once at bedtime | Athletic PerformanceReference report | 3-6 months continuous use, then 1-3 month break to prevent desensitization | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance. Source tabs Injectable | |||||
| SubQ | 30 mcg/kg daily | Once at bedtime | Pediatric GH DeficiencyReference report | 3-6 months continuous use, then 1-3 month break to prevent desensitization | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance. Source tabs Injectable | |||||
| IVIV bolus | 1 mcg/kg IV | Single dose | Diagnostic TestingReference report | 3-6 months continuous use, then 1-3 month break to prevent desensitization | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance. Source tabs Injectable | |||||
| SubQ | 200 mcg daily | 5 days weekly | Body CompositionReference report | 3-6 months continuous use, then 1-3 month break to prevent desensitization | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance. Source tabs Injectable | |||||
| SubQSubQ co-injection | 200 mcg + GHRP | Once daily | Combination TherapyReference report | 3-6 months continuous use, then 1-3 month break to prevent desensitization | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance. Source tabs Injectable | |||||
| IntranasalNasal spray or drops | 30+ mcg/kg | Once daily | Alternative to InjectionReference report | Similar to injection protocols - 3-6 months | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance. Source tabs Nasal | |||||
| IntranasalNasal administration | Equivalent to 200-300 mcg SC | Once at bedtime | Patient Preference ProtocolReference report | Similar to injection protocols - 3-6 months | 18 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance. Source tabs Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 3-6 months continuous use, then 1-3 month break to prevent desensitization
- Break
- 1-3 months off between cycles, or use 5 days on/2 days off schedule
Reported timing
Bedtime administration 2+ hours after last meal for optimal GH response
Nasal
- Use period
- Similar to injection protocols - 3-6 months
- Break
- 1-3 months between cycles to prevent tolerance
Reported timing
Bedtime administration preferred, ensure clear nasal passages
Side effects & safety
Short-lived local effects
Historical diagnostic label reports facial warmth/flushing and injection-site pain.
4Contraindications
That label excludes hypersensitivity, pregnancy and lactation.
4Specialist precautions
Diagnostic use required particular caution in diabetes or epilepsy.
4Monitoring
Thyroid function, glucose and IGF-1; local/nasal reactions.
Source exclusions
Active malignancy, pituitary tumors and pregnancy.
Stop symptoms
Headache/vision changes, allergy, severe local reactions, deteriorating glucose control or malignancy-related symptoms.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
10 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Octreotide
Avoidance reportedInhibits GH release.18
Reference report · Pep-Pedia label: Avoid CombinationLanreotide
Avoidance reportedInhibits GH release.18
Reference report · Pep-Pedia label: Avoid CombinationPrednisone
Caution reportedCan suppress response.18
Reference report · Pep-Pedia label: Use CautionInsulin
Caution reportedGlucose regulation.18
Reference report · Pep-Pedia label: Monitor CombinationGlucocorticoids, somatostatin or insulin
Label warningHistorical Geref label identifies interference with diagnostic GH responses.4
Research contextClonidine, levodopa or atropine
Label warningThese can alter the diagnostic response; this is test interpretation, not a general combination-safety endorsement.4
Research contextIpamorelin
Unverified pairingGH-axis pairing; benefits not established.18
Reference report · Pep-Pedia label: SynergisticCJC-1295
Unverified pairingOverlapping GHRH activity; form matters.18
Reference report · Pep-Pedia label: SynergisticGHRP-2
Unverified pairingGH-release potentiation.18
Reference report · Pep-Pedia label: SynergisticThyroid hormones
Unverified pairingReplacement only when indicated.18
Reference report · Pep-Pedia label: CompatibleNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
Historical Geref 50 instructions do not validate modern research powders.4
Diagnostic ampoule
The 50-mcg ampoule used at least 0.5 mL supplied 0.9% saline immediately before use; remainder discarded.4
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia names 3 mL BAC water but does not attach a vial mass to that volume.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- A concentration cannot be inferred from 3 mL alone. · Reported storage: 2–8°C for 10–30 days, depending on formulation.
The source describes gentle mixing and avoiding vigorous shaking.
Nasal
The nasal section emphasizes device calibration and refrigerated storage.
- Reported parameters
- It gives no numerical concentration or storage interval.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceClear reconstituted solutionReported appearancePharmaceutical grade purityReported appearanceProper cold chain storageReported appearanceFDA-registered manufacturingReported concernCloudy or discolored solutionReported concernIncorrect molecular weightReported variationRoom temperature exposure
18Vial sizes
5mg6
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
18Lyophilized: 2-8°C up to 3 years; Reconstituted: 2-8°C for 10-30 days
Refrigerate nasal formulations, protect from light
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
Limited human dataSource context
Geref discontinuation does not make compounded products approved; source stack labels are not clinical safety clearance.
Compound identity & other names
A GHRH fragment that stimulates growth-hormone release. Geref was previously approved and later discontinued; today's compounded or research products should not be presented as the historical approved product.
Other names: GHRH 1-29 · Geref
Historical Geref approval; discontinued. FDA determined its withdrawal was not for safety or effectiveness reasons.
How it may work
Pituitary GHRH receptors stimulate pulsatile GH and downstream IGF-1.18
Hormone response and clinical outcomes
A small study of nightly GHRH(1-29) in older men found increased nocturnal GH but no change in IGF-I. Some strength measures improved; that does not establish broad anti-aging benefit.
1Historical approval and discontinuation
FDA's 2013 notice found Geref products were not removed from sale for reasons of safety or effectiveness. This does not approve new sellers or longevity claims.
2Research areas and evidence gaps
GH secretion research. Small studies examined hormone and functional responses in older men.1
Historical diagnostic use. Geref evaluated pituitary GH reserve under specialist supervision.4
- Long-term effects on healthy adults and reliable clinical benefits for sleep, recovery or longevity remain uncertain.
- Results from related modified GHRH analogues should not automatically be assigned to sermorelin.
Community reports Unvalidated
Pep-Pedia describes sleep, recovery and body-composition expectations. These are secondary community claims, not established long-term clinical outcomes.5
A secondary protocol description, not a clinical recommendation or a representative survey. Dose, product identity, other compounds and outcome reporting are not independently verified.
Search coverage and review status
No additional 2025–2026 peer-reviewed efficacy trial of this exact product was identified in this targeted check. Earlier evidence and unresolved listed references are retained.
- Checked
- 2026-10-12
- Search
- sermorelin 2025 2026 trial site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 10 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
- Pep-Pedia maps nasal-administration and combination-study labels to a commentary/review; those claims are not independently verified.
- Citation mismatch: the listed GHRH study title corresponds to PMID 9005976, while Pep-Pedia links PMID 9005977.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Nightly GHRH(1-29) in healthy elderly menReview status not recorded
AI-PREPARED SUMMARY
Exploratory study reported more nocturnal GH without higher IGF-I and improvements in selected strength measures. It does not establish longevity benefits.
Hormone response and clinical outcomes
A small study of nightly GHRH(1-29) in older men found increased nocturnal GH but no change in IGF-I. Some strength measures improved; that does not establish broad anti-aging benefit.
2FDA determination on discontinued GerefReview status not recorded
AI-PREPARED SUMMARY
FDA determined Geref's discontinued products had not been withdrawn for safety or effectiveness reasons.
Historical approval and discontinuation
FDA's 2013 notice found Geref products were not removed from sale for reasons of safety or effectiveness. This does not approve new sellers or longevity claims.
3PubChem: sermorelin chemical identityReview status not recorded
AI-PREPARED SUMMARY
Records amidated GHRH(1–29), its molecular formula and molecular weight.
4Historical Irish Geref 50 product characteristicsReview status not recorded
AI-PREPARED SUMMARY
Historical diagnostic label with IV half-life, test interactions and formulation-specific saline preparation. It is not a current US research-powder label.
5Pep-Pedia: sermorelin — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Reports commonly discussed protocols; these schedules are unvalidated descriptions, not evidence of safety or efficacy.
6Research catalog: labeled vial examplesCatalog checked
AI-PREPARED SUMMARY
Catalog lists a 5 mg research vial. These are seller label examples, not verified contents, market-frequency estimates or supplier endorsements.
7Nasal Administration Study (1990s)Pep-Pedia maps nasal-administration and combination-study labels to a commentary/review; those claims are not independently verified.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source describes nasal GHRH delivery and 69% preference for it; exact analogue, exposure and comparator need checking.
Reported population / model
Adults
Reported study details
30+ μg/kg intranasal · Acute · 69% patient preference over injection · Additional card metadata — Synergistic Effects with GHRP-2 (Clinical): Adults·GHRH+GHRP-2·Acute·54-fold vs 20-fold GH increase
Synergistic Effects with GHRP-2 (Clinical): Combined GHRH/GHRP-2 reportedly produced larger acute GH release; this is not direct evidence for every sermorelin combination or chronic outcome.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Pep-Pedia maps nasal-administration and combination-study labels to a commentary/review; those claims are not independently verified. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Daily GHRH-(1-29) in GH-deficient children: first-year Geref study (1996)Pep-Pedia also assigns adult pharmacokinetic claims to this URL; the abstract concerns pediatric growth treatment.Abstract checked
AI-PREPARED SUMMARY
An open-label study treated 110 GH-deficient children with 30 micrograms/kg subcutaneously each evening for up to one year; 86 entered the efficacy analysis. Mean growth velocity rose from 4.1 to 8.0 cm/year at six months and 7.2 at twelve months. This paper is not an adult pharmacokinetic study and does not report 36 months of treatment.
Primary abstract checked during reference-card audit · Checked 2026-10-12
9GHRH-(1-29) hormone responses in older men (1992)The reference page combines six-week and body-composition descriptions under this URL; the checked abstract describes two 14-day courses.Abstract checked
AI-PREPARED SUMMARY
Ten older men received 0.5 mg and 1 mg GHRH-(1-29) subcutaneously twice daily, each for 14 days with a 14-day untreated interval. The higher dose raised GH and IGF-I toward young-comparator values. Blood pressure did not change; the abstract did not demonstrate the separate 1.26 kg lean-mass claim assigned to this URL.
Primary abstract checked during reference-card audit · Checked 2026-10-12
10Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiencyLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
11A potentially effective drug for patients with recurrent glioma: sermorelinLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
12Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal malesLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
13Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly menCitation mismatch: the listed GHRH study title corresponds to PMID 9005976, while Pep-Pedia links PMID 9005977.Linked reference · Not independently reviewed
REFERENCE NOTE
Pep-Pedia bibliography retained as listed. The correctly linked study is separately included as “Nightly GHRH(1-29) in healthy elderly men.”
Pep-Pedia bibliography · Checked 2026-10-12
14Growth hormone-releasing hormone therapy in growth hormone-deficient children: Geref International Study GroupLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
15Growth hormone secretagogues: history, mechanism of action, and clinical developmentLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
16Sermorelin acetate discontinuation - manufacturing, not safety relatedLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
17Pep-Pedia: Sermorelin — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 12 min and a peak time of 10 min. Stated attribution: FDA Geref Label (discontinued). The checked IV Geref label gives 6–7 minutes; the reference value is retained separately and must not replace route-specific label data. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
18Pep-Pedia: Sermorelin — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12